Why Amneal Pharmaceuticals Stock Is On Investors’ Radar

Amneal Pharmaceuticals (AMRX) has been drawing attention after a strong share price move over the past month and past 3 months, prompting investors to reassess what the current valuation implies.

The stock recently closed at US$16.21, and available data shows it trades at a discount to one independent intrinsic value estimate. This may interest readers comparing Amneal to other US biopharmaceutical companies.

Beyond the recent move, Amneal Pharmaceuticals has seen its share price return climb 30.5% over the past month and 36% over the past quarter, while the 1 year total shareholder return of 107.3% points to strong, sustained momentum rather than a short term spike.

If Amneal’s run has you thinking about where else growth stories might be emerging in healthcare, it could be worth scanning other specialist plays in the sector through our 40 healthcare AI stocks

With Amneal Pharmaceuticals trading at US$16.21, sitting below one intrinsic value estimate and 6.4% under one analyst price target, a key question is whether this gap reflects a potential opportunity or whether the current price already incorporates expectations about the company’s future.

Most Popular Narrative: 6.0% Undervalued

At a last close of $16.21 versus a narrative fair value of $17.25, Amneal Pharmaceuticals is framed as modestly undervalued, with that gap resting on some specific growth and profitability assumptions.

The analysts have a consensus price target of $17.25 for Amneal Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $19.0, and the most bearish reporting a price target of just $16.0.

Curious what underpins that $17.25 figure? The narrative leans on faster earnings growth than revenue, rising margins, and a future earnings multiple that assumes Amneal Pharmaceuticals closes some of the gap to peers. The mix of biosimilars, specialty drugs, and refinancing effects all feed into those projections, but the exact balance of each driver sits inside the detailed model.

Result: Fair Value of $17.25 (UNDERVALUED)

However, Amneal Pharmaceuticals still faces pressure from the highly competitive U.S. generics market and carries meaningful debt, both of which could challenge the current narrative.

Another View: Amneal Pharmaceuticals Through The Earnings Lens

The SWS fair value model suggests Amneal Pharmaceuticals is 66.6% below an estimate of its future cash flow value, yet on simple earnings metrics the stock looks expensive. At a P/E of 42.3x versus a fair ratio of 35.3x and a peer average of 19.8x, that gap raises questions about how much optimism is already in the price.

For investors weighing these mixed signals, it may help to see how the earnings based view stacks up in more detail through the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and concern around Amneal Pharmaceuticals resonates, do not wait for consensus to form. Instead, weigh the 3 key rewards and 3 important warning signs.

Looking For More Ideas Beyond Amneal Pharmaceuticals?

If Amneal Pharmaceuticals has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to quickly spot fresh, differentiated stock ideas that fit your style.

• Target potential upside with companies that combine quality and attractive pricing by reviewing the 45 high quality undervalued stocks.
• Strengthen your income stream by scanning for reliable payers in the 8 dividend fortresses.
• Prioritise resilience and capital preservation with the 65 resilient stocks with low risk scores, so you are not finding out about safer options after everyone else has moved.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.